• Member News

Stablepharma is delighted to announce another new recruit to the Science Team in Spain

Stablepharma announce another new recruit to the Science team in Madrid, Spain based at Stablepharma’s R&D Center of Excellence (CoE) in Qube Technology Park

Medannex’s monoclonal antibody MDX-124 highly active in pancreatic cancer models

Data shows powerful synergy in combination with standard cancer treatments

Virology Research Services Chooses Discovery Park as it relocates London team

A team of virologists move to Discovery Park to expand operations. Demand for lab and manufacturing space continues at Discovery Park to support the UK’s booming life science industry.

BioIVT Launches GMP Grade Human AB Serum to Facilitate the Development and Manufacturing of Cell and Gene Therapies

This cell culture supplement can be used to manufacture both autologous and allogeneic cell therapies.

Arecor commences US phase I clinical trial of AT247 ultra-rapid insulin in combination with an insulin pump

First patient dosed in potential game-changing diabetes combination therapy

The Oxford Science Park appoints Jitesh Patel as Development Manager

New role enables accelerated delivery of buildings for existing & new occupiers

Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

Pneumagen is a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs).

Ori Biotech raises over $100 million in Series B funding to launch innovative cell and gene therapy manufacturing platform

Funds will allow for a rapid transition through pre-commercialization to market launch

PhoreMost expands into new facility at Unity Campus, Cambridge, UK

New state-of-the-art facility has been designed to support PhoreMost’s phenotypic screening expertise. Investment in new headquarters and equipment forms part of ongoing company growth plans.

eXmoor Pharma secures contract to work with New Zealand Blood Service

eXmoor Pharma, experts in strategic and technical biomanufacturing, specialising in cell and gene therapy, has signed a deal to work with the New Zealand Blood Service (NZBS). Bristol-based eXmoor, which has worked in over 15 countries worldwide, will be providing NZBS with valuable Quality support as they build and establish a new site near Auckland.